RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda The Bracelet-1 resutls were signficantly successful and have demonstrated pelareorep's single agent anti-cancer activity.
As pointed out beforehand, it was necessary to differentiate pelareorep's effectiveness from other agents that pelareorep may be combined with.
With respect to the Bracelet-1 study, the patients enrolled in the three cohorts were heavily pre-treated and had failed previously administered chemotherpy, endocrine (i.e. tamoxifen) and CDK 4/6 inhbitor therapies and were considered "salvage" patients. We ned to keep in mind that anti-PD-1 checkpoint inhibitor therapy does not respond to patients who may have been heavily pre-treated with chemotherapy. (no ORR, PFS or OS improvements are experienced, as witnessed in other studies)
Conversely Bracelet-1 demonstrated that pelareorep (single agent) + paciltaxel is a significanty active therapy showing vast;y improved ORR, PFS, HR and CI readings over the standard of care (SOC) paclitaxel control cohort.
So the administration of pelareorep in earlier breast cancer patients should improve the surrogate endpoints even furher to that seen in the Bracelet-1 Phase 2 study.